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Abstract
Background Targeted therapies significantly improve clinical outcomes among patients with metastatic renal cell carcinoma
(mRCC). Several new agents have been approved for first- and second-line use. However, there is a lack of compelling evidence
comparing sequencing strategies, and available comparative data regarding the real-world effectiveness of different therapeutic
sequences are limited.
Materials and Methods We identified mRCC patients who initiated targeted therapy between January 1, 2008 and May 31, 2017
from the National Health Insurance Fund (NHIF) database of Hungary. Overall survival (OS) and duration of first-line treatment
(DFT) were obtained for patients receiving sunitinib-everolimus, sunitinib-axitinib, or pazopanib-everolimus treatment se-
quences. OS of sunitinib-everolimus and sunitinib-axitinib sequences was also determined for patients having better or worse
response to sunitinib first-line therapy.
Results MedianOSwas significantly longer among patients treated with sunitinib-axitinib compared to those receiving sunitinib-
everolimus. Median DFTwas also significantly longer in the sunitinib-axitinib vs. sunitinib-everolimus group. Sunitinib-axitinib
was associated with significantly longer median OS compared to sunitinib-everolimus in patients with better response to first-line
sunitinib in the pooled sunitinib population. In patients with worse response to sunitinib, sunitinib-axitinib was associated with a
trend towards greater OS compared to sunitinib-everolimus, but the difference did not reach statistical significance.
Conclusions In this nationwide database analysis, mRCC patients treated with the sunitinib-axitinib sequence had significantly
longer OS compared to those receiving sunitinib-everolimus therapy. The OS benefits of second-line axitinib were consistent
among patients with better response to sunitinib defined by DFT values.
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Introduction
Vascular endothelial growth factor (VEGF) and its receptors
have a central role in the development and progression of renal
cell cancer (RCC). The activation of VEGF-driven signal
transduction pathways promotes tumor angiogenesis, growth
and proliferation, as well as survival of malignant cells
through the induction of expression of various anti-apoptotic
factors [1, 2]. Targeting VEGF pathways either by VEGF
ligand-binding blockade or by the inhibition of downstream
signaling by VEGF receptor (VEGFR) inhibitors has become
the mainstay of systemic treatment for metastatic RCC both in
first and second line [3]. Eight of the 12 agents ever approved
for the treatment of mRCC are anti-VEGFR agents (sorafenib,
sunitinib, pazopanib, tivozanib, axitinib, cabozantinib, and
lenvatinib), which inhibit tumor angiogenesis to varying de-
grees. These targeted therapies provide higher efficacy (in
terms of PFS or OS) compared to the previous standard-of-
care [4, 5].
Sunitinib is a highly potent, oral, multitargeted receptor
tyrosine kinase inhibitor (TKI) which inhibits VEGFR-1, -2,
and ! 3, and a number of other receptor tyrosine kinases
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including platelet-derived growth factor receptor (PDGFR)-!
and -" [6]. In its registration trial, sunitinib showed significant
clinical benefits over IFN-! in the first-line treatment of
mRCC patients and was approved for the treatment of
mRCC in 2006. Sunitinib is recommended by international
and national guidelines as one of the standard first-line treat-
ment options for mRCC patients with good or intermediate
prognosis based on the Memorial Sloan Kettering Cancer
Center (MSKCC) criteria [7–10].
Despite the well-defined benefits of sunitinib, disease
progression usually occurs after 6–15 months, and even-
tually sunitinib resistance develops in almost all patients.
The mechanism of sunitinib resistance is thought to be
multifactorial and is not yet fully understood [11–13].
Before the approval of nivolumab, cabozantinib and the
lenvatinib-everolimus combination in 2018, options for
second-line therapy for patients with advanced RCC
who had progressed after initial VEGF-targeted systemic
therapy included the VEGFR TKI axitinib [14] or the
mammalian target of rapamycin inhibitor (mTORi) evero-
limus [15]. However, in the absence of head-to-head com-
parative second-line studies and validated biomarkers or
clinical parameters which could predict the outcomes of a
specific second-line therapy, clinicians are faced with the
challenge of choosing between a growing number of
available second-line agents. In the lack of proper guid-
ance and validated data, treatment decisions often remain
empiric and based on physician and patient preferences or
toxicity profiles rather than high-quality evidence.
Therefore, further studies are needed to optimize the se-
quence of targeted therapies for mRCC patients to provide
further insights into the real-world effectiveness and safe-
ty profile of available regimens and treatment sequences.
This challenge remained further exciting after the intro-
duction of combined TKI and immunotherapy combina-
tion in first line setting.
Targeted therapies and their sequences were gradually
incorporated into Hungarian clinical practice after their
international approval for the treatment of mRCC.
Sunitinib has been reimbursed in Hungary for the first
-line treatment in good and intermediate risk of this
disease since 2010, while pazopanib gained approval
as first-line therapy in 2014. As per reimbursement
rules, first-line pazopanib can only be followed by
everolimus, which has been reimbursed since 2014 for
second-line treatment after sunitinib or pazopanib.
Axitinib has also been reimbursed since 2014 but only
for second-line treatment after first-line sunitinib
therapy.
The present analysis investigated OS and DFTamong real-
world mRCC patients receiving sunitinib-everolimus, suniti-
nib-axitinib, or pazopanib-everolimus sequential treatments in
Hungary.
Patients and Methods
This was a nationwide retrospective database analysis using
prescription claims data from the database of the NHIF. The
NHIF database contains prescription claims data of all reim-
bursed medicinal products from all Hungarian patients.
Patients were selected for the research if they had at least
one reimbursed prescription claim at a public pharmacy be-
tween January 1, 2008 and May 31, 2017 for any of the fol-
lowing drugs: IFN-!/IL-2, sorafenib, sunitinib, everolimus,
axitinib, pazopanib, temsirolimus. The primary aim of our
study was to determine the impact of approved targeted treat-
ment sequences, namely, sunitinib-everolimus, sunitinib-axi-
tinib, and pazopanib-everolimus on OS of patients with
mRCC. We focused on patients treated these sequential
targeted therapies where we could identify the exact date of
first-line treatment initiation.
The analysis included patients who had the ICD-10 code
C64 (‘Malignant neoplasm of kidney, except renal pelvis’).
This identification process yielded a pool of social security
numbers denoting mRCC patients who had received pharma-
cological treatment for mRCC during the examined period.
Since the NHIF database only contains reimbursed pre-
scription claims data, non-reimbursed claims were not includ-
ed in the analysis, and we did not have any information about
the proportion of patients receiving drugs on the basis of in-
dividual import or in a clinical trial. The database does not
contain laboratory data (e.g. glucose levels, hemoglobin A1c,
lipids), patient parameters (e.g. body mass index), information
on harmful addictions (e.g. alcohol or tobacco use), or prog-
nostic features. Since we did not have any information on the
baseline prognostic features of patients (e.g. TNM staging,
MSKCC prognostic allocation or previous nephrectomy) re-
ceiving different sequential treatments, we used a reverse de-
duction method to adjust for this confounding. In order to
create patient groups with similar response to first-line suniti-
nib, we pooled patients from the sunitinib-everolimus and
sunitinib-axitinib groups and lined them up in a decreasing
order of DFT. We divided them into two cohorts based on
DFT in a way that both cohorts included the same number
of patients. The so-called “upper 50%” cohort included pa-
tients who responded better to sunitinib (i.e. those with longer
DFT, while those with poorer response (i.e. with shorter DFT,
constituted the “lower 50%” cohort. The establishment of pa-
tient cohorts with similar baseline disease severity allowed us
to perform informative comparisons between sunitinib-based
sequential treatment groups.
The mathematical algorithm required for analysis was de-
signed and provided by RxTarget Statistical Programming and
Analysis Ltd. using SQL programming language based on a
preliminary study plan, and was submitted via email to NHIF.
Anonymized data were provided by NHIF in an aggregated
form without any individual identification parameter based on
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a specific permit (NHIF approval number: S04/77/2017), with
the strict consideration of data protection rules.
OS, defined as the time period between the initiation of
first-line pharmacological therapy and death, and DFT, de-
fined as the time period between the initiation of first-line
pharmacological therapy and the initiation of second-line
treatment were estimated using the Kaplan-Meier method
and analyzed by log-rank test and Cox regression analysis.
Overall statistical analysis was carried out using the R
Software version 3.4.2 (09-28-2017) with the application of
‘survival’, ‘survminer’, ‘multicomp’, and ‘cowphw’
packages.
The Ethical Hungarian Medical Research Council ap-
proved the study (licence number: OGYÉI/31936-1/2017).
Results
Between January 1 2008 and May 31 2017 318 patients were
treated on sunitinib-everolimus (mean age: 60.9 years), 128
patients on sunitinib-axitinib (mean age: 62.1 years), and 66
patients on pazopanib-everolimus (mean age: 60.6 years) se-
quential therapy.
Figure 1 shows the OS of patients treated with sunitinib-
everolimus, sunitinib-axitinib or pazopanib-everolimus
starting from the initiation of first-line therapy. Patients with
mRCC receiving sunitinib-axitinib had significantly longer
median OS compared to those receiving the sunitinib-
everolimus sequence (median OS: 41.0 vs. 21.7 months; p <
0.0001; HR: 0.55 [0.42–0.72]). Median OS of patients receiv-
ing the pazopanib-everolimus or sunitinib-everolimus se-
quences appeared to be similar. However, the pazopanib-
everolimus sequence could not be directly compared to
sunitinib-based sequences due to differences in first-line
therapy.
The DFT of mRCC patients is shown on Fig. 2. Median
DFT was significantly longer among patients treated with
sunitinib-axitinib compared to those receiving the sunitinib-
everolimus sequence (median DFT: 19 vs. 11.7 months; HR:
0.53 [0.42–0.67]; p < 0.0001).
In order to adjust for potential differences in baseline prog-
nostic features of the disease between patient groups, we cre-
ated patient populations with different response to sunitinib
from the pooled population of the sunitinib-everolimus and
sunitinib-axitinib patient groups. Using DFT, as described pre-
viously both the “upper 50%” (sunitinib-everolimus: n = 139;
sunitinib-axitinib: n = 84) and “lower 50%” (sunitinib-axitin-
ib: n = 44; sunitinib-everolimus: n = 179) cohorts included
223 patients, with the median DFT being 14 months in the
pooled sunitinib population. Figure 3 shows the OS of patients
with better response to sunitinib defined as longer DFT, i.e.
the “upper 50%. In this cohort, patients receiving sunitinib-
axitinib sequential treatment showed significantly longer me-
dian OS than those treated with the sunitinib-everolimus se-
quence (median OS: 52.8 vs. 41.1 months; p = 0.0019; HR:
0.57 [0.38–0.83]). There was no statistically significant differ-
ence in OS with sunitinib-axitinib among patients with poorer
response to sunitinib, i.e. the “lower 50%”, although there was
a numerical trend towards longer OS with sunitinib-axitinib
(median OS: 18.1 vs. 16.0 months; HR: 0.86 [0.56–1.29]; p =
0.462).
Since we found significantly better OS among patients
treated with second-line axitinib after sunitinib compared to
second-line everolimus, we examined the hypothetical surviv-
al gain in years that the sunitinib-axitinib sequence could have
provided to “upper 50%” patients who received second-line
everolimus therapy (n = 139). The total number of years sur-
vived in this patient group since the initiation of first-line
sunitinib was 475. Our analysis showed that the
Fig. 1 Overall survival from the
initiation of first-line therapy
among patients with mRCC
receiving sunitinib-everolimus,
sunitinib-axitinib, or pazopanib-
everolimus sequential treatment
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administration of the sunitinib-axitinib sequence instead of
sunitinib-everolimus would have resulted in an additional sur-
vival gain of + 85 years among these 139 patients. Therefore,
treating all patients who responded better to sunitinib based on
DFT (“upper 50%”) with sunitinib-axitinib would have pro-
vided significant survival benefits for this patient group.
Discussion
This retrospective database analysis investigated the impact of
sequences onOS ofmRCC patients during the period between
January 1 2008 and May 31, 2017. Patients with mRCC re-
ceiving sunitinib-axitinib sequential therapy had significantly
longer OS compared to those treated with the sunitinib-
everolimus sequence and resulted survival gain. However, it
was not known whether patients receiving different sequential
treatments had different disease prognosis at baseline, which
may have influenced overall study results.
One possible explanation for better OS associated with
second-line axitinib vs. everolimus is that patients receiving
the sunitinib-axitinib sequence had better prognosis at base-
line compared to those treated with sunitinib-everolimus. Our
findings related to DFT support this assumption as rapid pro-
gression on first-line therapy could reflect baseline prognostic
features. Indeed, earlier progression could be seen among pa-
tients treated with the sunitinib-everolimus sequence (Fig. 2),
suggesting that they might have had worse prognosis at base-
line, than those treated with sunitinib-axitinib. These patient
population may represent the bad responders to first line su-
nitinib therapy.
To allow for the comparability of OS with different treat-
ment sequences, we stratified patients receiving sunitinib-
axitinib or sunitinib-everolimus according to DFT. The OS
benefit of the sunitinib-axitinib sequence remained consistent
Fig. 2 Duration of first-line treat-
ment among patients with mRCC
receiving sunitinib-everolimus or
sunitinib-axitinib sequential
treatment
Fig. 3 Overall survival among
patients with better response to
first-line sunitinib therapy who
received the sunitinib-everolimus
or sunitinib-axitinib sequence
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in patient cohorts with similar response to first-line sunitinib
therapy. To our knowledge, this is the first published analysis
which reports OS data in a real-world population of mRCC
patients receiving targeted sequential treatments using the
Hungarian NHIF database.
The development of VEGF and VEGFR TKI inhibitors
revolutionized the treatment of mRCC. Currently, the most
commonly used agents are the tyrosine kinase inhibitors suni-
tinib and pazopanib, for the first-line treatment of mRCC pa-
tients with good or intermediate prognosis [7] stratified by
MSKCC risk criteria based on phase III clinical trials [16,
17]. The effectiveness and tolerability of both agents have
been confirmed by real-world studies [18, 19]. Everolimus
and axitinib emerged as safe and effective second-line treat-
ment options for mRCC patients after progression on VEGF-
targeted therapy [14, 20]. However, currently there is no clear
guidance on the optimal choice of agents in the second and
additional lines of therapy in mRCC, and evidence comparing
different sequential regimens is limited to retrospective obser-
vational studies [21–24].
Since the present analysis, significant advances have been
made in the landscape of first- and second-line therapy in
mRCC.
The randomized Phase III CheckMate 214 trial demonstrat-
ed that combination therapy with nivolumab and ipilimumab
improved OS compared with sunitinib and received regulato-
ry approvel for treatment naive patients with IMDC interme-
diate and poor risk disease in 2018. Cabozantinib can also be
used as first-line therapy due to the results of CABOSUN
phase II trial [25] in mRCC of intermediate or high risk group.
The phase III JAVELIN trial of avelumab plus axitinib also
recently reported improved PFS in this patient’s population
compared with sunitinib [26]. KEYNOTE-426 with
pembrolizumab and axitinib combination reported improved
OS and PFS outcomes versus sunitinib monotherapy in first-
line setting [27]. The phase II IMotion 150 trial showed also
promising PFS and ORR with combination of atezolizumab
and bevacizumab comparedwith sunitinib, but the OSwas not
better [28]. Concerning the new data sunitinib is indicated in
patients with good risk disease in countries where new inno-
vative treatment is available. In other countries the standard of
treatment remains sunitinib as first-line of choice in good and
intermediate risk group [29–32].
In second-line therapy cabozantinib showed significantly
improved OS, objective response rate (ORR), and PFS com-
pared to everolimus in the large, phase III METEOR trial [33],
and was subsequently approved for second-line treatment af-
ter prior anti-VEGF therapy among patients with advanced
RCC. Lenvatinib, a multi-TKI of VEGFR1–3, fibroblast
growth factor (FGF) receptors 1–4, PDGFR!, RET, and
KIT also gained approval after showing improved ORR,
PFS, and OS in combination with everolimus compared to
everolimus alone in a phase II randomized study [34]. The
phase III CheckMate-025 study with nivolumab showed sig-
nificant improvements in OS and ORR when compared to
everolimus among patients with previously treated advanced
RCC [35]. Based on these findings, nivolumab was the first
immune checkpoint inhibitor to be approved in this setting
[36].
At the time of our analysis, the first-line therapy consisted
of treatment with sunitinib or pazopanib, neither nivolumab
nor cabozantinib were available as second-line treatment. Our
analysis focused on differences in OS among mRCC patients
treated with the sunitinib-everolimus or sunitinib-axitinib
sequences.
Previous real-world studies comparing the effectiveness of
second-line targeted therapies for mRCC used different de-
signs and reported heterogeneous results, with no convincing
evidence of a difference in effectiveness between mTORi and
VEGF TKI in the second-line setting [37]. Our results build
on the existing real-world evidence which supports the bene-
fits of second-line axitinib treatment over everolimus after
prior anti-VEGF therapy [38–40] in patients showing longer
DFT on first-line sunitinib treatment.
The main strength of our study lies in the characteristics of
the NHIF database which contains all reimbursed medications
from all Hungarian mRCC patients receiving targeted therapy
over a nearly 9,5-year period.
This study has several limitations which need to be consid-
ered when interpreting the results. First, the NHIF prescription
claims database does not include any information on patient
characteristics, laboratory data, vital signs, baseline prognostic
features. A propensity-score based method would have
allowed for baseline covariate adjustment, but such ap-
proaches could not be applied due to the lack of information
of patient characteristics and laboratory data. The adjustment
of patient cohorts based on DFTwas meant to at least partially
eliminate this confounding. Second, in the present study, only
effectiveness was evaluated with no assessment of tolerability,
which means that we do not have any reliable information
about treatment discontinuation and dose reductions.
It is important to emphasize that the decision-making pro-
cess during the selection of sequential therapy should always
be tailored to the individual patient and should involve the
careful consideration of patient-related factors including age,
prognosis of malignant disease, comorbidities, concomitant
medications, compliance as well as potential side effects of
therapy. As new evidence is rapidly emerging, it is crucial to
discover reliable biomarkers that may help determine the best
treatment option for the right patient [41].
Conclusions
In a real-world population of patients withmetastatic renal cell
carcinoma, sunitinib-axitinib sequential therapy was
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associated with improved OS and PFS than the sunitinib-
everolimus sequence. Further studies are needed to identify
molecular biomarkers that may guide the optimal sequencing
of agents and allow for a tailored approach in this patient
population.
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